The FDA approved the new recombinant, adjuvanted zoster vaccine (Shingrix, GlaxoSmithKline) for the prevention of shingles (herpes zoster) in adults aged 50 years and older.
Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses. It combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity as people age.